GE HealthCare's Acquisition of icometrix: A Leap Towards Enhanced Neurological Care

Strengthening Neurological Solutions

The anticipated acquisition aligns with GE HealthCare’s precision care strategy. The goal is to strengthen the company’s portfolio of offerings in neurological care and enhance its quantitative analysis of brain MRI.

icometrix’s icobrain platform offers a comprehensive set of solutions for neurological disease analysis. This includes icobrain aria, the first AI Computer-Aided Detection and Diagnosis FDA 510(k) cleared solution. It detects known side effects of amyloid targeting therapies used to treat Alzheimer’s disease.

CHICAGO — Sept. 10, 2025 — GE HealthCare (Nasdaq: GEHC) today announced it has entered into an agreement to acquire icometrix. This company focuses on providing AI-powered brain imaging analysis for neurological disorders, such as Alzheimer’s disease. The acquisition aims to meet the growing demand for MRI in personalized treatment planning.

To complement its MR-guided AI-assisted scanning expertise, GE HealthCare expects to integrate the icometrix icobrain platform with its MRI systems. This will create a seamless workflow for analysis and reporting in neurological disease assessment. icobrain aria includes the first FDA-cleared computer-aided detection and diagnosis solution for detecting and quantifying known side effects of amyloid targeting therapies, known as Amyloid Related Imaging Abnormalities (ARIA).

Growing Demand for Neurological MRI

According to the Alzheimer’s Association, studies predict that the number of adults living with Alzheimer’s disease will double by 2050[1]. As new anti-amyloid therapies receive global approvals, the demand for more frequent neurological MRI exams continues to rise. MRI technology is crucial for assessing treatment eligibility and monitoring potential side effects, such as brain swelling and microbleeds, of amyloid targeting therapies.

“This effort marks a pivotal step in our journey to advance precision care in neurology,” said Roland Rott, President and CEO of Imaging at GE HealthCare. “By integrating icometrix’s AI-powered insights with our advanced imaging technologies, we aim to empower care teams with the clarity and confidence needed to navigate complex neurological conditions.”

Enhancing Clinical Decision Support

The planned acquisition of icometrix aligns with GE HealthCare’s precision care strategy. It is expected to strengthen the company’s clinical decision support applications for timely diagnosis and monitoring throughout the neuro treatment pathways. This will offer enhanced patient access to the technology.

The company’s current neuro solutions portfolio includes MR and PET scanners, pharmaceutical diagnostics, and MIMneuro Software digital solutions. These support quantification for amyloid imaging, enabling GE HealthCare to provide holistic neuro solutions for its customers.

“Along with our commitment to pushing the barriers of neuroscience research with our innovative MRI technology, we’re dedicated to strengthening our neurology portfolio and our MR imaging capabilities,” said Kelly Londy, President & CEO of MR at GE HealthCare. “Our anticipated acquisition of icometrix and its icobrain solutions supports our goal to help clinicians deliver high-quality, timely care to meet this increased demand in MR technology.”

Seamless Integration of Technologies

GE HealthCare intends to focus on expanding patient access to the icobrain aria solution on all vendor MRI systems. This will be achieved through both commercial distribution and clinical integration. The icobrain aria solution identifies both forms of ARIA: ARIA-E and ARIA-H from MR scans. It performs longitudinal analysis of ARIA occurrence over time.

This solution provides radiologists with tools for monitoring Alzheimer’s patients receiving anti-amyloid therapies throughout their treatment. This supports both patient care and operational efficiency. Integrating this solution with GE HealthCare’s current MR systems and technologies, such as its deep learning offerings AIR x ™ Brain, AIR Recon DL, and SONIC DL 3D, is expected to enable a seamless, optimized workflow. This will allow clinicians to manage the increased volume of scans without compromising the quality of care.

Comprehensive Solutions for Neurological Disorders

The icometrix suite of solutions includes tools that assist radiologists and neurologists in comparing and quantifying brain MR scans over time. These tools are useful for disorders ranging from multiple sclerosis, dementia, epilepsy, stroke, and traumatic brain injury, among others.

This product suite also features a strong pipeline of clinical decision support applications in development. These applications aim to improve neurological care in the future.

“Building on our existing relationship, we are excited by the prospect of joining GE HealthCare,” said Wim Van Hecke, icometrix CEO. “We aim to leverage icometrix’s innovation talents and customer relationships to continue to improve the diagnostic and treatment journey for both neurological clinicians and their patients. Together, we aim to leverage our complementary technology to address the complexities of managing neurological care.”

About icometrix

Founded in 2011 and based in Leuven, Belgium, icometrix provides AI-powered brain imaging analysis through its icobrain platform. This platform offers clinicians valuable insights into neurological disorders. icobrain extracts key data from brain MRI scans, facilitating more accurate diagnoses and personalized treatment plans across hospitals globally.

Furthermore, icometrix collaborates with pharmaceutical companies to support strategic drug development, clinical trials, real-world evidence, and market access needs. For more information, visit icometrix.com.

The consummation of the transaction is subject to customary closing conditions, including regulatory approvals. Financial details of the transaction have not been disclosed publicly. GE HealthCare intends to fund this transaction with cash on hand.

Forward-Looking Statements

This release contains forward-looking statements. These statements might be identified by words and variations of words such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction, and GE HealthCare Technologies Inc.’s (the “Company’s”) performance, growth opportunities, and strategy.

These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters.

Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.